Enrico Guarnera, Igor N Berezovsky, Allosteric drugs and mutations: chances, challenges, and necessity, Current Opinion in Structural Biology, Volume 62, 2020, Pages 149-157, ISSN 0959-440X, https://doi.org/10.1016/j.sbi.2020.01.010.
Allosteric drugs have become an indispensable toolbox of rapidly developing precision medicine, having already established reputation of advantages over traditional medicines. Allosteric mechanisms are also widely involved in the action of SNPs and latent cancer drivers, and can be used in fine and specific tuning of biologics, providing a great potential in diagnostics and therapy. We discuss here major targets for prospected allosteric medicines, currently available allosteric compounds, and drug-candidates at different stages of research and (pre)clinical trials. We describe our computational model of the comprehensive allosteric control of protein activity, outlining the ways of implementing it in pharmacological applications. Finally, we formulate outstanding questions and discuss feasible directions in the work on allosteric drugs and mutations.
This research is supported by core funding from the Bioinformatics Institute, ARES.